2GY.F PHC HOLDINGS CORP.
- Market cap
- EUR 966M
- P/E
- 18.5x
- P/B
- 1.02x
- ROE
- 0.3%
- Dividend yield
- 3.17%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is 2GY.F undervalued?
Graham number2GY.F trades 8.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PHC HOLDINGS CORP. fundamental analysis
No fundamental analysis for PHC HOLDINGS CORP. yet.
PHC HOLDINGS CORP. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PHC HOLDINGS CORP.
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management, Healthcare Solutions, and Diagnostics & Life Sciences. It offers precision anatomical pathology for cancer, including tissue processors, digital pathology, and histology consumables; cell growth and preservation, such as CFC-free ultra-low tem…
Full company profilePHC HOLDINGS CORP. financial statements
PHC HOLDINGS CORP. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 340B | 356B | 354B | 362B | 364B |
| Gross Profit | 165B | 169B | 158B | 166B | 165B |
| Operating Income | 8.53B | 20.5B | 1.74B | 23.0B | 22.6B |
| EBITDA | - | 49.4B | 30.1B | 52.0B | 50.1B |
| Net Income | -8.46B | -3.22B | -12.9B | 10.5B | 492M |
| EPS | -68 | -26 | -102 | 83 | 3.89 |
| Balance Sheet | |||||
| Total Assets | 591B | 562B | 564B | 532B | 543B |
| Total Liabilities | 455B | 423B | 425B | 391B | 382B |
| Shareholders' Equity | 135B | 138B | 140B | 142B | 162B |
| Cash & Short-term Investments | 95.2B | 60.9B | 47.0B | 39.6B | 39.8B |
| Cash Flow | |||||
| Operating Cash Flow | 51.1B | 21.4B | 41.3B | 41.9B | 42.5B |
| Capital Expenditure | 11.7B | 11.5B | 14.6B | 11.6B | 9.09B |
| Free Cash Flow | 39.3B | 9.86B | 26.7B | 30.3B | 33.4B |
| Ratios | |||||
| ROE | -6.2% | -2.3% | -9.2% | 7.4% | 0.3% |
| ROA | -1.4% | -0.6% | -2.3% | 2.0% | 0.1% |
| Net Profit Margin | -2.5% | -0.9% | -3.6% | 2.9% | 0.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PHC HOLDINGS CORP. dividends
- Dividend yield
- 3.17%
- Forward dividend
- 0.24 EUR
- Payout ratio
- 1,078.5%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 5.31B | 42 | 1,078.5% |
| 2025 | JPY 4.92B | 39 | 46.9% |
| 2024 | JPY 9.04B | 72 | - |
| 2023 | JPY 9.20B | 73 | - |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns PHC HOLDINGS CORP.
- Insiders 56.90%
- Institutions 9.22%
- Public & others 33.88%
- Shares outstanding 127M
- Free float 50.7M
PHC HOLDINGS CORP. company profile
- Company name
- PHC HOLDINGS CORP.
- Ticker
- 2GY.F
- ISIN
- JP3801300009
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 8,647
- Fiscal year end
- March
- Address
- Dai-ichi Life Hibiya First, Chiyoda, Japan, 100-8403
- Phone
- 81 3 6695 9938
- Website
- phchd.com
About PHC HOLDINGS CORP.
PHC Holdings Corporation, together with its subsidiaries, provides healthcare digital and precision technology solutions in Japan, Europe, North America, and internationally. The company operates in three segments: Diabetes Management, Healthcare Solutions, and Diagnostics & Life Sciences. It offers precision anatomical pathology for cancer, including tissue processors, digital pathology, and histology consumables; cell growth and preservation, such as CFC-free ultra-low temperature freezers, CO2 incubators, and live cell metabolic analyzer and cell expansion bioreactor system; and diagnostic testing comprising clinical testing, diagnostic reagents, and digital diabetes management solutions. The company also provides patient record and billing solutions, which include electronic medical record systems and receipt systems, systems for pharmacies, and wellness and prevention; diabetes management technology, such as blood and continuous glucose monitoring systems; and medical device and drug delivery comprising contract development and manufacturing services, drug delivery systems, and digital health. It serves patients, healthcare professionals, and researchers. The company was formerly known as Panasonic Healthcare Holdings Co., Ltd. and changed its name to PHC Holdings Corporation in April 2018. PHC Holdings Corporation was founded in 1948 and is headquartered in Chiyoda, Japan.
PHC HOLDINGS CORP. management
10- Ms. Kyoko DeguchiPresident, CEO & Chairman · born 1965
- Mr. Koichiro SatoSenior EVP, Chief Strategy Officer, COO & Representative Director · born 1973
- Mr. Kaiju YamaguchiSenior Executive Corporate Officer, CFO & Director · born 1978
- Ryuichi HirashimaSr. Exec Corp Officer, Chief Administrative Officer, Chief HR Officer & CTO
- Nobuaki NakamuraExecutive Corporate Officer and Head of Diagnostics & Life Sciences Domain
- Steven LynumCorporate Officer
- Hideaki TakahashiCorporate Officer & Head of Healthcare IT Solutions Division
- Kenichi UchinoCorporate Officer
- Takahide WatanabeCorporate Officer
- Peter BodlundCorporate Officer & Head of Diabetes Management Division